FDA approves new pertuzumab biosimilar - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA approves new pertuzumab biosimilar

  • By

  • Mouj Hijazi

  • November 17, 2026

  • 2 min

Share

Clinical Scorecard: FDA approves new pertuzumab biosimilar

At a Glance

CategoryDetail
ConditionHER2-positive breast cancer
Key MechanismsPertuzumab-qcay (Pebrilzo) is a HER2-targeting monoclonal antibody and biosimilar to pertuzumab (Perjeta).
Target PopulationAdults with HER2-positive breast cancer in metastatic, neoadjuvant, or adjuvant treatment settings.
Care SettingCombination treatment for metastatic and early breast cancer; the earliest licensed US launch date is the third quarter of 2028.

Key Highlights

  • The FDA approved pertuzumab-qcay for adults with HER2-positive breast cancer.
  • For metastatic disease, it is approved with trastuzumab and docetaxel for patients without prior anti-HER2 therapy or chemotherapy for metastatic breast cancer.
  • For neoadjuvant treatment, it is approved with trastuzumab and chemotherapy for locally advanced, inflammatory, or early-stage disease involving tumors larger than 2 cm or positive lymph nodes.
  • For adjuvant treatment, it is approved with trastuzumab and chemotherapy for patients at high risk of recurrence.
  • Biocon reports that comparative evidence showed high similarity to reference pertuzumab without clinically meaningful differences in quality, safety, efficacy, or immunogenicity.

Guideline-Based Recommendations

Diagnosis

    Management

    • Use pertuzumab-qcay with trastuzumab and docetaxel for eligible metastatic disease.
    • Use pertuzumab-qcay with trastuzumab and chemotherapy for the specified neoadjuvant or high-risk adjuvant settings.
    • Do not use in patients with known hypersensitivity to pertuzumab or its excipients.

    Monitoring & Follow-up

    • Assess left ventricular ejection fraction before and during treatment.

    Risks

    • Boxed warnings include left ventricular dysfunction and embryo-fetal toxicity.
    • Serious infusion-related reactions, hypersensitivity, and anaphylaxis are warnings.
    • Common adverse reactions associated with pertuzumab-containing regimens include diarrhea, alopecia, neutropenia, nausea, fatigue, and peripheral neuropathy.

    Patient & Prescribing Data

    Adults with HER2-positive breast cancer; metastatic use is for patients who have not previously received anti-HER2 therapy or chemotherapy for metastatic disease.

    Approved in combination with trastuzumab and docetaxel for metastatic disease, and with trastuzumab and chemotherapy for specified neoadjuvant and adjuvant settings. Earliest licensed US launch date: third quarter of 2028.

    Clinical Best Practices

    • Assess left ventricular ejection fraction before and during treatment.
    • Review the boxed warnings and risks of infusion-related reactions, hypersensitivity, and anaphylaxis.
    • Avoid use in patients with known hypersensitivity to pertuzumab or its excipients.

    Related Resources & Content

    Original Source(s)

    Related Content